Best Practices for Monitoring and Management Of Teprotumumab-Induced Hearing Impairment

News
Article

Sponsored Supplement: Best Practices for Monitoring and Management Of Teprotumumab-Induced Hearing Impairment

Teprotumumab is the first and only FDA-approved medication for thyroid eye disease (TED). Teprotumumab has demonstrated efficacy in improving proptosis, diplopia, measures of quality of life, and inflammation in patients with TED. In pivotal trials, however, 10% of patients treated with teprotumumab reported otologic symptoms, and higher rates have been reported in clinical practice. This sponsored supplement reviews the evidence to date on teprotumumab-associated hearing impairment, risk factors for developing hearing loss, and best practices for assessing, monitoring, and managing hearing issues in patients being considered for teprotumumab therapy.

© 2024 MJH Life Sciences

All rights reserved.